PD-L1Pep-2

PD-L1Pep-2: sourced facts only. name: "Sequential treatment with IL4RPep-1-KLA followed by PD-L1Pep-2, a PD-L1-blocking peptide, during the co-culture of tumor cells and CD8+ T-cells activated T-cell activity including T-cell proliferation and cytokine secretion more efficiently than single treatment with IL4RPep-1-KLA or PD-L1Pep-2, or simultaneous treatment." [DOI:10.1158/1538-7445.am2022-3422]; target: "Sequential treatment with IL4RPep-1-KLA followed by PD-L1Pep-2, a PD-L1-blocking peptide, during the co-culture of tumor cells and CD8+ T-cells activated T-cell activity including T-cell proliferation and cytokine secretion more efficiently than single treatment with IL4RPep-1-KLA or PD-L1Pep-2, or simultaneous treatment." [DOI:10.1158/1538-7445.am2022-3422]; developer: "1School of Medicine, Kyungpook National University, Daegu, Republic of Korea." [DOI:10.1158/1538-7445.am2022-3422]; modality: "Sequential treatment with IL4RPep-1-KLA followed by PD-L1Pep-2, a PD-L1-blocking peptide, during the co-culture of tumor cells and CD8+ T-cells activated T-cell activity including T-cell proliferation and cytokine secretion more efficiently than single treatment with IL4RPep-1-KLA or PD-L1Pep-2, or simultaneous treatment." [DOI:10.1158/1538-7445.am2022-3422]